M&A Deal Summary

Trillium Therapeutics Acquires Fluorinov Pharma

On January 27, 2016, Trillium Therapeutics acquired life science company Fluorinov Pharma for 45M CAD

Acquisition Highlights
  • This is Trillium Therapeutics’ 1st transaction in the Life Science sector.
  • This is Trillium Therapeutics’ 0th largest (disclosed) transaction.
  • This is Trillium Therapeutics’ 1st transaction in Canada.
  • This is Trillium Therapeutics’ 1st transaction in Ontario.

M&A Deal Summary
Date 2016-01-27
Target Fluorinov Pharma
Sector Life Science
Buyer(s) Trillium Therapeutics
Deal Type Add-on Acquisition
Deal Value 45M CAD

Target

Fluorinov Pharma

Toronto, Ontario, Canada
Fluorinov Pharma Inc. is a privately-held oncology company. Fluorinov has developed a proprietary medicinal chemistry platform using unique fluorine chemistry, which permits the creation of new chemical entities from validated drugs and drug candidates with improved pharmacological properties, potentially leading to increased safety and efficacy.

Search 199,968 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Trillium Therapeutics

Toronto, Ontario, Canada
Category Company
Founded 2004
Sector Life Science
Employees33
DESCRIPTION

Trillium Therapeutics is an immuno-oncology company developing innovative therapies for the treatment of cancer. Company lead program SIRP?Fc is an antibody-like fusion protein that blocks the activity of CD47, a molecule that allows tumor cells to escape destruction by the immune system. Trillium Therapeutics was founded in 2004 and is based in Mississauga, Canada.

DEAL STATS #
Overall 1 of 1
Sector (Life Science) 1 of 1
Type (Add-on Acquisition) 1 of 1
State (Ontario) 1 of 1
Country (Canada) 1 of 1
Year (2016) 1 of 1
Mergr

Product

Company

Legal